Clinical Trials Browser

Prostatic Neoplasms

NCT05704634 2026-04-15

A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.

Phase 1 Active not recruiting

56 enrolled

Thoracic

Lung Neoplasms

NCT03017820 2026-04-13

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Phase 1 Recruiting

127 enrolled

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Immunoblastic Lymphadenopathy, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT06508463 2026-04-13

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

Phase 1 Recruiting

21 enrolled

Lymphoid

Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic

NCT05064085 2026-04-06

Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer

Phase 1 Completed

13 enrolled

Breast

Breast Neoplasms

NCT04722523 2026-03-30

A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer

Phase 1 Recruiting

40 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04387084 2026-03-23

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

Phase 1 Active not recruiting

10 enrolled

Dermatologic

Skin Neoplasms

NCT07404332 2026-02-11

5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

Phase 1 Not yet recruiting

35 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT06902376 2025-11-05

NEO-COMBATXL

Phase 1 Recruiting

12 enrolled

EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

NCT04826393 2025-10-22

ASP8374 + Cemiplimab in Recurrent Glioma

Phase 1 Completed

14 enrolled

CNSLymphoid

Glioblastoma, Glioma, Lymphoma, Follicular

NCT04428671 2025-08-14

Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer

Phase 1 Recruiting

20 enrolled

Metastatic Skin Squamous Cell Carcinoma

NCT03477864 2025-04-29

Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer

Phase 1 Withdrawn

Genitourinary

Prostatic Neoplasms

NCT04729725 2023-08-14

SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL

Phase 1 Terminated

3 enrolled

Tumor-Agnostic

Neoplasm Metastasis

Clinical Trials

A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC

A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer

A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

NEO-COMBATXL

ASP8374 + Cemiplimab in Recurrent Glioma

Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer

Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer

SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL